BioCentury
ARTICLE | Product Development

Feb. 3 Product Development Quick Takes: European Commission’s €10M coronavirus program; plus Seqirus, Seattle Genetics, Merck, Lilly, NIAID

February 4, 2020 1:25 AM UTC
Updated on Feb 11, 2020 at 12:27 AM UTC

EC outlines €10M coronavirus program
The European Commission said it will use €10 million from its Horizon 2020 program to fund research into prevention and treatment of 2019-nCoV acute respiratory disease. The funding is expected to support two to four projects. Under a Horizon 2020 provision for public health emergencies, applicants will be subject to rapid data-sharing requirements; the deadline for applications is Feb. 12.

FDA approves Seqirus’ cell-based pandemic flu vaccine
Audenz influenza A (H5N1) monovalent vaccine, adjuvanted from Seqirus gained FDA approval Friday to prevent infection by influenza A virus subtype H5N1 in individuals ages six months and older. The CSL Ltd. (ASX:CSL) subsidiary said it is the first adjuvanted, cell-based pandemic flu vaccine made via cell-based antigen manufacturing. It contains the company’s MF59 adjuvant...